NCT07790003Completed
Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
This qualitative research study, based on semi-structured interviews and a focus group, aims to explore the attitudes of prostate cancer patients on active surveillance (AS) towards dietary fibre supplementation, given the potential benefits demonstrated in previous research. Prostate cancer patients on AS, often overlooked in the literature, experience cyclical anxiety, particularly regarding disease progression. Lifestyle modifications, including dietary changes, are pursued by a number of these patients as a preventative measure. Dietary fibre such as inulin and psyllium have promising results in studies of pelvic cancers. However, it is important to note that these findings do not directly apply to patients who are currently undergoing AS for prostate cancer. Despite potential side effects, these dietary fibres may contribute to anti-inflammatory and antitumorigenic effects. Building on this evidence, the investigators aim to explore patient perspectives on the feasibility and acceptability of dietary fibre supplementation during AS. The insights gained will guide the development of a feasibility and/or pilot studies and, subsequently, a multicentre randomised controlled trial. If successful, this intervention could potentially reshape clinical practice for patients with prostate cancer on AS.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 11 Mar 2024
- Start date
- 3 Jul 2024
- Primary completion date
- 22 Oct 2024
- Lead sponsor
- University of Aberdeen
- Diseases
- Prostate cancer
- NCT number
- NCT07790003
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 3 Jul 2024 to the primary completion date, 22 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who were treated with surgery, radiotherapy, chemotherapy or anti-androgen therapy for their prostate cancer.
Other
- Participants who do not speak fluent English will be excluded from this study.
- Vulnerable participants, classified as adults who do not have the capacity to consent for themselves, will not be included in the study. If the research team are made aware that someone has lost capacity then they will be withdrawn from the study.
Who the study is looking for
- Participants over 18 years of age.
- Participants with residence in North-East Scotland.
- Participants must be fluent in the English language.
- Participants on active surveillance.
Age in the registry: 18 years to - · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NHS Grampian - Aberdeen Royal Infirmary Coordinator of this site? Confirm its status | Aberdeen | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.